Drugs of abuse test wins FDA clearance
A
Randox Laboratories product story
Edited by the Laboratorytalk editorial team
Sep 12, 2005
Biochip allows detection of amphetamine, methamphetamine, cocaine, barbiturates, cannabinoids, opiates, methadone, benzodiazepines, lorazepam, phencyclidine and creatinine from a single urine sample
Randox has received FDA clearance for its Drugs of Abuse array for use on the evidence analyser.
The multi-analyte biochip allows the simultaneous detection of amphetamine, methamphetamine, cocaine, barbiturates, cannabinoids, opiates, methadone, benzodiazepines, lorazepam, phencyclidine and creatinine from a single urine sample.
The company says the evidence analyser is at the forefront of biochip array technology, offering the latest technological advances in clinical analysis.
Not what you're looking for? Search the site.
Contact Randox Laboratories
Tel (United Kingdom) 044 28 9442 2413
Other Randox Laboratories stories
-
Detect ten drugs of abuse on one biochip
Drugs of abuse arrays improve efficiency and reduce costs through high throughput screening, simple sample preparation, reduced sample and reagent volumes and multi-analyte reagents and controls -
Randox offers kits for therapeutic drug monitoring
Randox Therapeutic Drug Monitoring kits offer accurate determination of drugs in a patient's blood, ensuring that they receive the most effective dosage of medication with the least possible toxicity. -
Randox adds liquid QC to Acusera range
The Randox Acusera range of quality-control sera is to expand with the introduction of the liquid ready-to-use QC. -
Randox offers true third-party quality controls
Randox Laboratories has announced that it produces true third-party quality control serum to guarantee independent performance assessment for diagnostic devices, methods and reagents. -
Randox develops drugs-of-abuse testing procedure
Randox has developed a multi-marker drugs-of-abuse (DoA) testing procedure for rapid drug screening programmes.
Browse by category
